The role of core hospital of cancer genomic medicine and regional cooperation

Research output: Contribution to journalArticlepeer-review

Abstract

Two genomic profiling assays have been approved by Japanese national health insurance in December 2018. Japanese government assigned core hospitals, which can conduct molecular tumor board, called "expert panel" to make a therapeutic recommendation based on the genomic findings and concentrated the function of cancer genomic medicine. The genomic profiling tests under Japanese national health insurance system must be covered for the entire population. To eliminate regional disparities of such an advanced medicine, the infrastructure to spread cancer genomic medicine for collaborating among hospitals should be established. Here, we introduce our efforts to make regional collaboration in Tohoku University Hospital.

Original languageEnglish
Pages (from-to)1149-1152
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume47
Issue number8
Publication statusPublished - 2020 Aug

Keywords

  • Cancer genomic medicine
  • Institutional collaboration
  • Molecular tumor board

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The role of core hospital of cancer genomic medicine and regional cooperation'. Together they form a unique fingerprint.

Cite this